Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
14 mai 2024 16h00 HE
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...
$1.6+ Billion Anti-Venom Markets - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F: Next-Generation Anti-Venoms & Precision Medicine Approaches
13 mai 2024 10h52 HE
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Anti-Venom Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's...
Global Hepatitis B Vaccines Business Research Report 2024: Market to Reach $3.9 Billion by 2030 from $2.9 Billion in 2023 with Combination Vaccines Accounting for $2.6 Billion
13 mai 2024 09h58 HE
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Hepatitis B Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Hepatitis B Vaccines Market...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 16h05 HE
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout,...
Dyadic to Attend Industry and Investor Events in May
08 mai 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Infectious Vaccine Collaboration, Development, Research and Licensing Deals Trends Report 2024 with Directory of 522 Agreements Signed Since 2019
07 mai 2024 06h37 HE
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Infectious Vaccine...
Global Vaccine Delivery Devices Market Report 2024-2032: Device, Route of Administration, End User, and Regional Analysis and Forecasts
07 mai 2024 05h24 HE
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Delivery Devices Market Report by Device, Route of Administration, End User, and Region 2024-2032" report has been added to ...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
02 mai 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Global Anti-Venom Analysis Report 2024: A $1.95 Billion Market by 2032 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical
30 avr. 2024 10h37 HE
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-Venom Market Report by Type, Animal Type, End User, Region and Company Analysis 2024-2032" report has been added to ...
Pfizer's ABRYSVO (RSVpreF) for Respiratory Syncytial Virus (RSV) in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2023-2032
30 avr. 2024 04h40 HE
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "ABRYSVO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...